Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02988466 · ClinicalTrials.gov registry record · Phase 2
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
NCT02988466 is a Phase 2 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 78 participants.
The verdict
NCT02988466, a Phase 2 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
Study Summary
This is a single institution phase II study of a reduced intensity conditioning (RIC) followed by a haploidentical hematopoietic cell transplant (haplo-HCT) in persons with diagnosis of hematologic malignancy. Conditioning will consists of fludarabine, cyclophosphamide, melphalan and total body irradiation (TBI) preparative regimen with a melphalan dose reduction for patients ≥55 years old and those with HCT Comorbidity Index (CI) \>3. This study uses a two-stage phase II design with accrual goal of 84 patients, using 28 patients separately for arms A, C and D
Interventions
- DRUG GVHD Prophylaxis
- BIOLOGICAL Haplo HCT <55 years old
- BIOLOGICAL Haplo HCT ≥55 years old
- BIOLOGICAL Haplo HCT ≥55 and < 65 years old
- BIOLOGICAL Haplo HCT ≥65 and ≤75 years old
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2017-01-24 |
| Est. Completion | 2025-03-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02988466
The ClinicalTrials.gov registry entry for NCT02988466 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which GVHD Prophylaxis is the first listed.
NCT02988466 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02988466 about?
NCT02988466 is a clinical study titled "Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT". This is a single institution phase II study of a reduced intensity conditioning (RIC) followed by a haploidentical hematopoietic cell transplant (haplo-HCT) in persons with diagnosis of hematologic malignancy. Conditioning will consists of fludarabine, cyclophosphamide, melphalan and total body irra...
What is the current status of trial NCT02988466?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2017-01-24. Estimated completion is 2025-03-24.
What interventions are being tested in trial NCT02988466?
The interventions under investigation include: GVHD Prophylaxis (DRUG), Haplo HCT <55 years old (BIOLOGICAL), Haplo HCT ≥55 years old (BIOLOGICAL), Haplo HCT ≥55 and < 65 years old (BIOLOGICAL), Haplo HCT ≥65 and ≤75 years old (BIOLOGICAL).
Who is sponsoring clinical trial NCT02988466?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.